Clinical TrialCrossoverNitrous OxideNitrous OxidePlaceboCompleted

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.

Ask Blossom about this trial

Target Enrollment

Not specified

Study Type

Phase II interventional

Design

Randomized

Registry

CTG / NCT03283670

Study Arms & Interventions

50% nitrous oxide

experimental

Single 1-hour inhalation of 50% nitrous oxide in oxygen

Interventions

Nitrous Oxide50 %
via Inhalation• single dose• 1 doses total
balanced with air/oxygen

25% nitrous oxide

experimental

Single 1-hour inhalation of 25% nitrous oxide in oxygen

Interventions

Nitrous Oxide25 %
via Inhalation• single dose• 1 doses total
balanced with air/oxygen

Placebo

placebo

Single 1-hour inhalation of placebo (air/oxygen)

Related Publications

PaywallindividualPrimary

A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression

In a phase 2 trial, inhaled nitrous oxide at 25% concentration improved symptoms of treatment‑resistant major depression and produced fewer adverse effects than the 50% concentration.

Published: June 9, 2021
Journal: Science Translational Medicine
Authors: Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., Jain, N., Cheng, W. W. L., Komen, H., Yee, B., Bolzenius, J. D., Janski, A., Gibbons, R., Zorumski, C. F., Conway, C. R.

Company

Product

Legal

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

Study Arms & Interventions

50% nitrous oxide

Interventions

25% nitrous oxide

Interventions

Placebo

Related Publications

A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression

Interventions

Study Details

Study Team

Sponsors & Collaborators